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(PCR)Abstract Objective: Diabetes has long been known to be an independent risk factor for
cardiovascular disease. Recognition of diabetic individuals at greatest risk of developing coronary
artery disease (CAD) would have important public health importance by allowing the distribution
of limited resources to be directed on those who would most beneﬁt from aggressive management.
Several functional differences between haptoglobin (Hp) phenotypes have been demonstrated that
appear to have important biological and clinical consequences in the development of CAD in
patients with type 2 DM. The present study was conducted to demonstrate the relationship between
258 G. Hamdy et al.the Hp phenotypes and the development of CAD among Egyptian patients with type 2 DM. To our
knowledge this work had not been carried out in Egypt before.
Subjects and methods: The study included 160 subjects divided into three groups. Group I: 72
type 2 DM patients without CAD, Group II: 48 type 2DM patients with developed CAD, Group
III: 40 age and gender matched apparently healthy subjects to serve as controls. All patients and
controls were subjected to full history taking, complete clinical examination, and routine laboratory
investigations. Serum C-reactive protein (CRP) levels and serum haptoglobin levels were measured.
Polymerase chain reaction (PCR) was used for Hp phenotypes’ determination.
Results: Analysis revealed association between Hp2-2 phenotype and the presence of CAD in
type 2 DM. Hp and CRP serum levels were signiﬁcantly higher in patients with CAD. Although
the levels of Hp did not reach signiﬁcance among patients with different Hp phenotypes yet the indi-
vidual with Hp2-2 phenotype had trend toward higher level.
Conclusion: Hp2-2 phenotype is considered to be a major susceptibility gene for the development
of CAD in type 2 DM. Awareness of this gene susceptibility should raise future research for proper
treatment and prevention of CAD development in type 2 DM.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Regardless of efforts and advances in management, patients
with type 2 diabetes Mellitus (type 2 DM) represent a signiﬁ-
cant global health problem and continue to be at high risk
of cardiovascular complications. Risk factors such as hyper-
tension, hyperlipidemia, and cigarette smoking independently
increase the risk to the DM patient of developing CAD, but
the effect of DM appears to be independent of conventional
risk factors [1]. Identifying genes that contribute to complica-
tion development has been challenging. The susceptibility to
diabetic complications is partially controlled by complex
unknown genetic factors. One such genetic factor appears to
be a functional allelic polymorphism in the haptoglobin (Hp)
gene [2–4].
Haptoglobin (Hp) is an acute phase protein synthesized
primarily in the liver, and to a lesser extent in other tissues
including the lung, skin, spleen, and kidney in response to
inﬂammatory cytokines [5]. It is a plasma a2-glycoprotein.
Hp possesses an innate phenotype-dependent antioxidant,
one of its main functions is to bind oxygenated, free hemoglo-
bin with stabilization of the heme iron within hemoglobin (Hb)
[6] and thereby prevents the oxidative tissue damage in areas of
inﬂammation that may be mediated or catalyzed by free hemo-
globin through the generation of highly reactive oxygen species
which promotes endothelial activation and inﬂammation lead-
ing to endothelial dysfunction [7]. The Hp–Hb complex is rap-
idly removed from circulation via monocyte–macrophage cell
surface scavenger receptor (CD163) mediated endocytosis by
hepatic Kupfer cells [8]. Several lines of evidence have sug-
gested the role for pro-inﬂammatory cytokines in regulating
insulin action and glucose homeostasis. Type 2 diabetic
patients exhibit higher serum levels of pro-inﬂammatory
cytokines and acute-phase reactants [9]. Diabetes mellitus is
also associated with increased oxidative stress and imbalance
of antioxidant defense mechanism, that results in damage of
several cellular bio molecules [10] .The role of Hp in regulation
of inﬂammation suggests a potential role in type 2DM patho-
genesis [11–12]. The ability of haptoglobin to protect against
hemoglobin driven oxidative injury is abrogated when
hemoglobin becomes glycated, a process that is markedly
accelerated in the diabetic state. Glycohemoglobin–haptoglobincomplexes are catalytically redox active and therefore the rate
at which haptoglobin–hemoglobin complexes are cleared from
the serum and extravascular space is of heightened importance
in the diabetic state [13].
Hp is composed of four chains: 2 a chains and 2 b-chains. a
and b chains are encoded by a single gene and are synthesized
as a single polypeptide chain that is proteolytically cleaved into
a short a chain and a long b chain that remain connected
through a disulﬁde bond [14]. In humans, Hp is characterized
by a genetic polymorphism which arises from differences in a
chains while b chains are identical in all Hp types. The Hp
locus is located on chromosome 16 (16q22.1). Two common
alleles exist for Hp, Hp1 and Hp2 that give rise to three major
phenotypes. Individuals homozygous for allele Hp1 express
the phenotype 1-1, those homozygous for allele Hp2, express
phenotype Hp2-2, and heterozygous individuals express phe-
notype Hp1-2 [15–16]. A link between Hp polymorphism
and a broad range of pathological conditions has been demon-
strated, and such associations probably reﬂect functional dif-
ferences among the phenotypes [17].
A key discrepancy between the alleles is that the protein
product of the Hp1 allele has a more potent antioxidant com-
pared with that produced by the Hp2 allele [18]. This func-
tional allelic polymorphism in the haptoglobin gene, may
determine susceptibility to a wide variety of vascular disorders
associated with an increase in oxidative stress [4,19–20].
There exists a growing body of evidence that diabetic vascu-
lar disease develops only in those patients who are genetically
susceptible. Diabetic individuals homozygous for the hapto-
globin 2 allele (Hp2-2) are at signiﬁcantly greater risk of devel-
oping cardiovascular disease as compared with diabetic
individuals homozygous for the haptoglobin 1 allele (Hp1-1)
with an intermediate risk being found in the heterozygote [2].
Hp1-1–Hb complexes are cleared much more rapidly than
Hp2-2–Hb complexes by CD163 (monocyte–macrophage scav-
enger receptor) providing one mechanism for decreased oxida-
tive stress and cardiovascular disease in Hp1-1 diabetic
patients [13].
To our knowledge, there is no study conducted to clarify
the relationship between haptoglobin polymorphisms of
Egyptian type 2 DM and the development of CAD. Therefore
this study is designed to investigate the distribution of Hp
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out CAD compared to healthy subjects. We also investigated
the relationship between different Hp phenotypes and other
conventional risk factors involved in the pathogenesis of car-
diovascular diseases. The serum levels of inﬂammatory mark-
ers namely CRP and Hp were examined.
2. Subjects and methods
2.1. Study design and subjects
From November 2011 to August 2013, 120 patients with type-2
DM who attended the Internal Medicine departments, Faculty
of medicine, Cairo and Al Azhar universities were studied.
They were divided into 2 groups. Group I included 72 type 2
diabetic patients (45 males and 27 females) without CAD;
Group II included 48 type 2 diabetic patients with CAD (33
males and 15 females). A third group of 40 age and gender
matched apparently healthy subjects (28 males and 12 females)
serving as controls was included. They were recruited from vol-
unteers of blood donation attending the above Hospitals. Con-
trol subjects were normal fasting and postprandial blood sugar,
free of clinical manifestations of CAD by history, physical
examination and electro-cardiographic (EEG) ﬁndings. Each
patient was subjected to full physical examination. The clinical
history of each patient including demographic data with tracing
of the major traditional CAD risk factors (age, sex, hyperten-
sion, dyslipidemia, family history of premature cardiovascular
disease, and current smoking), disease condition and treatment
history was also recorded. Participants were weighed in light
clothing without shoes and their heights were measured. Body
Mass Index (BMI) was calculated by the Quetelet’s index, as
weight (kg)/height2 (m). The mean of two blood pressure
(BP) readings, measured on the right arm after participants
had been seated for 5 min, was recorded. Hypertension was
deﬁned as systolic blood pressure P140 mmHg or diastolic
blood pressure P90 mmHg or self reported use of antihyper-
tensive medication. The diagnosis of type 2DM was based on
the World Health Organization criteria [21]. CAD was deﬁned
as angina, ischemic electrocardiogram, myocardial infarction
conﬁrmed by Q-waves on electrocardiogram or hospital
records, angiographic stenosis >50%, or revascularization.
The work is carried out in accordance with the Code of
Ethics of the World Medical Association (Declaration of Hel-
sinki) for experiments involving humans .The study was
approved by the human research ethics committee of the hos-
pital, and informed consent was obtained from each patient.
Exclusion criteria included patients who had a diagnosis of
diabetic nephropathy, abnormal liver functions, CAD due to
any cause other than DM, chronic inﬂammatory diseases,
acute infections, hematologic disorders, acutely ill patients,
malignancy, and pregnant women.
2.2. Blood Sampling
After overnight fasting blood samples were collected from
patients and controls in both heparinized vacutainer and a
plain vacutainer to obtain plasma and serum respectively.
After centrifugation at 3000 rpm for 15 min, aliquots of
plasma and serum were stored at 80 C until analysis. Total
cholesterol (TC), triglycerides (TG), low density Lipoproteincholesterol (LDL-c), high density lipoprotein cholesterol
(HDL-c), fasting (FBS) and postprandial blood glucose
(2hsBS), and HbA1c were determined by Integra-400 (Roche
Diagnostics, Mannheim, Germany).
2.3. Assessment of serum haptoglobin (Hp) and C-reactive
protein (CRP)
CRP was done by Eleceyes (Roche-Germany). Serum concen-
trations of haptoglobin were done by a latex immunoturbidi-
metric method using Turbi Quick analyzer (vital Diagnostics,
Italy).
2.4. Determination of Hp polymorphism by PCR
GenomicDNAwas extracted fromwhole peripheral blood sam-
ples using the QIAamp DNA blood isolation Kit supplied by
(Qiagen, Germany). PCR was done to analyze the Hp1 and
Hp2 alleles by amethod described previously byKoch et al. [22].
Two different PCR primers (synthesized by Applied Biosys-
tems) were used for haptoglobin genotyping and subtyping
[23]:
Primer A: 50-GAGGGGAGCTTGCCTTTCCATTG-30;
was used for ampliﬁcation of a 1500-bp Hp 1 allele-speciﬁc
sequence.
Primer B: 50-GAGATTTTTGAGCCCTGGCTGGT-30;
was used for ampliﬁcation of a 3481-bp Hp 2 allele-speciﬁc
sequence.
The 1· PCR buffer, 1.5 mM MgCl2, and 0.2 mM dNTPs
were added to 0.4 lM of each primer, and 2 units of Qiagen
taq DNA polymerase to a ﬁnal volume of 50 lL containing
10–20 ng of genomic DNA. The PCR was performed under
the following conditions: an initial incubation at 95 C for
2 min, 35 cycles of incubation at 95 C for 1 min, 69 C for
40 s, and 72 C for 90 s, then at 72 C for 7 min for ﬁnal exten-
sion. The thermocyclers used were GeneAmp PCR systems
9700 and the 9600 mode (Applied Biosystems).
PCR products were digested using the DraI restriction
enzyme (Invitrogen), applied to electrophoresis in 1.5% aga-
rose gel, stained with ethidium bromide solution and identiﬁed
by transillumination using ultraviolet light. The haptoglobin
genotypes and subtypes were conﬁrmed according to the size
of the fragments obtained (Fig. 1).
2.5. Statistical analysis
Data were statistically analyzed using SPSS (Statistical Pack-
age for Social Science) computer program for statistical anal-
ysis, (version 15; Inc., Chicago. IL). The qualitative data
were expressed as frequency and percent, and quantitative data
were shown as mean ± SD. Student’s (t) test was used for
comparison between two groups having quantitative normally
distributed data, and One way analysis of Variance (ANOVA)
test was used for comparison between three or more groups
having quantitative normally distributed data and post hoc
test was performed. Chi-square (v2) test was used to compare
the qualitative variables. The allele frequencies were calculated
for a two-allele system and differences in haptoglobin genotype
and subtype frequencies between groups were compared using
(v2) test. P-value was considered statistically signiﬁcant when it
is less than 0.05.
1        2        3          4        5        6        7         8         9     10       M 
Figure 1 The ampliﬁcation products of Hp phenotypes: lanes 1,
2, 3, 6, 7 and 8 representing Hp1-1 (1500 bp), lanes 4 and 10
representing Hp2-1 (3841/1500 bp) and lanes 5 and 9 for Hp2-2
(3841 bp) and M representing MW size ladder band.
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3.1. Patients’ risk factors
This study comprised 120 patients with type 2 DM of them 48
patients had documented CAD. As shown in Table 1 signiﬁ-
cantly higher percentage of those patients with CAD suffered
from hypertension, dyslipidemia and also had signiﬁcantly
higher family history of CAD.
3.2. Demographic and laboratory data
Table 2 summarizes the main demographic and laboratory
data of the studied groups. There were no signiﬁcant differ-
ences between groups in terms of age, total cholesterol and tri-
glyceride levels. Diabetic groups showed signiﬁcantly higher
systolic and diastolic blood pressures (SBP and DBP) com-
pared to controls. Also diabetic groups showed signiﬁcantly
higher FBS, 2hsBS, HbA1c and LDL-c while HDL-c was sig-
niﬁcantly lower compared to the controls.Table 1 Risk factors of the studied groups.
Parameters Controls (N= 40) DM (N
Gender male (%) 28 (70) 45 (62.5)
BMI (kg/m2) 27.9 ± 3.1 30.2 ± 3
Disease duration (years) – 5.5 ± 2.
DM – 3.9 ± 1.
CAD
Family history of DM N (%) 8 (20) 50 (69.4)
Family history CAD N (%) 6 (15) 19 (26.4)
Current smokers N (%) 13 (32.5) 26 (36.1)
Hypertension N (%) – 21 (29.2)
Dyslipidemia N (%) – 20 (27.8)
P1 = DM versus controls; P2 = DM with CAD versus controls; P3 = D
P values < 0.05 and <0.01 are statistically signiﬁcant. NS, none signiﬁc
artery disease.3.3. Inﬂammatory markers
As regards the studied inﬂammatory markers, serum Hp level
was signiﬁcantly higher in diabetic patients with CAD
(mean ± SD, 149.3 ± 8.4) compared to controls (mean ±
SD, 78.2 ± 11.2) and diabetic patients without CAD
(mean ± SD, 126.1 ± 10.5) (P< 0.001, P< 0.05 respec-
tively). In the latter group, its level was signiﬁcantly higher than
controls (P< 0.01) (Fig. 2). Also serum CRP level was signif-
icantly higher in diabetic patients with CAD (mean ± SD,
1.3 ± 0.7) compared to controls (mean ± SD, 0.43 ± 0.07)
and diabetic patients without CAD (mean ± SD, 0.9 ± 0.2)
(P< 0.01, P< 0.05, respectively). In the latter group, its level
was signiﬁcantly higher than controls (P< 0.05) as shown in
Table 2.
3.4. Distribution of the Hp phenotypes among the studied groups
Table 3 shows that 42.5% of the Egyptian type 2 DM were of
Hp2-2 phenotype compared to 15% of the healthy controls.
Conversely 16.7% of patients with type 2 DM had Hp1-1 phe-
notype compared to 40% of the healthy controls. The fre-
quency of Hp2-1 was 40.8% and 45% for diabetic
individuals and controls respectively. Among the diabetic
patients, those with CAD had higher frequency of Hp2-2
(62.5%) compared to controls and diabetic patients without
evidence of CAD (15% and 29.2%) (P< 0.001; P< 0.01,
respectively). Signiﬁcant number of diabetic patients without
evidence of CAD had higher Hp2-2 compared to controls
(P< 0.05). A high frequency of Hp1 Allele was found among
the controls (0.625) while Hp2 allele was more frequent among
diabetic patients with CAD (0.750) as shown in Table 4.
3.5. The relationship between various CVD risk factors and
haptoglobin phenotypes in patient groups
As shown in Table 5 diabetic patient with Hp2-2 phenotype
had signiﬁcantly higher BMI compared to Hp1-1. Also
Hp2-2 phenotype had signiﬁcant higher HbA1c and CRP
serum levels and were more hypertensive and dyslipidemic
compared to other phenotypes. Hp serum level did not differ
signiﬁcantly between phenotypes however Hp2-2 individual
showed tendency toward higher levels.= 72) DM with CAD (N= 48) P-value
33 (68.8) NS
.2 32.2 ± 4.6 NS
1 6.13 ± 1.9
3 – NS
32 (66.7) P1 < 0.01; P2 < 0.01
27 (56.3) P2 < 0.01; P3 < 0.05
20 (41.7) NS
36 (75) P3 < 0.01
23 (47.9) P3 < 0.05
M versus DM with CAD.
ant; BMI, body mass index; DM, diabetes mellitus; CAD, coronary
Table 2 Demographic and laboratory data between patient and control groups.
Parameters Controls (N= 40)
M± SD
DM (N= 72)
M± SD
DM with CAD (N= 48)
M± SD
P-value
Age (years) 45.2 ± 3.1 49.3 ± 5.8 54.6 ± 8.9 NS
SBP (mmHg) 112.8 ± 5.2 139.5 ± 12.3 142.3 ± 9.3 P1 < 0.05; P2 < 0.05
DBP (mmHg) 72.3 ± 9.5 89.3 ± 10.4 92.3 ± 14.1 P1 < 0.05; P2 < 0.05
FBS (mg/dL) 78 ± 4.5 149.3 ± 11.6 153.2 ± 16.4 P1 < 0.01; P2 < 0.01
2hsBS (mg/dL) 99.6 ± 3.7 215.8 ± 26.1 224.8 ± 28.3 P1 < 0.001; P2 < 0.001
HbA1c (%) 5.3 ± 0.4 8.6 ± 2.5 9.23 ± 2.8 P1 < 0.05; P2 < 0.05
Cholesterol (mg/dL) 178.4 ± 9.2 189 ± 9.2 194.5 ± 11.7 NS
Triglycerides (mg/dL) 152 ± 27.7 151.4 ± 31.5 160 ± 23.7 NS
HDL-c (mg/dL) 42.3 ± 4.2 31.4 ± 4.9 28.3 ± 6.2 P1 < 0.05; P2 < 0.05
LDL-c (mg/dL) 108.2 ± 3.5 139 ± 11.7 144.6 ± 10.3 P1 < 0.05; P2 < 0.05
Haptoglobin (mg/dlL) 78.2 ± 11.2 126.1 ± 10.5 149.3 ± 8.4 P1 < 0.01; P2 < 0.001; P3 < 0.05
CRP (mg/dL) 0.43 ± 0.07 0.9 ± 0.2 1.3 ± 0.7 P1 < 0.05; P2 < 0.01; P3 < 0.05
P1 = DM versus controls; P2 = DM with CAD versus controls; P3 = DM versus DM with CAD. P values <0.05 and <0.01 are statistically
signiﬁcant. NS, none signiﬁcant; DM, diabetes mellitus; CAD, coronary artery disease; SBP, systolic blood pressure; DBP, diastolic blood
pressure; FBS, fasting blood sugar; 2hsBS, 2 hours postprandial blood glucose; HDL-c, high density lipoprotein cholesterol; LDL-c, low density
lipoprotein cholesterol); CRP, serum C-reactive protein.
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Figure 2 The serum levels of haptoglobin among the three
studied groups.
Table 3 Haptogolin phenotypes in patient and control groups.
Parameters Controls (N= 40) Total patients (N= 120) DM (N=
Hp1-1 16 (40%) 20 (16.7%) 14 (19.4%
Hp2-1 18 (45%) 49 (40.8) 37 (51.4%
Hp2-2 6 (15%) 51 (42.5) 21 (29.2%
P1 = DM versus controls; P2 = DM with CAD versus controls; P3 = D
signiﬁcant. NS, none signiﬁcant; DM, diabetes mellitus; CAD, coronary
Table 4 Hp allele frequencies in patient and control groups.
Parameters Controls (N= 40) Total patients
Hp*1 allele frequency 0.625 0.375
Hp*2 allele frequency 0.375 0.625
Hp, haptoglobin; DM, diabetes mellitus; CAD, coronary artery disease.
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Cardiovascular disease continues to disproportionately affect
individuals with diabetes worldwide despite signiﬁcant
advances in prevention efforts and medical care for these
patients. It has therefore become apparent that genetic predis-
position plays a key role in the development of vascular com-
plications in diabetes, and a functional polymorphism in the
Hp gene has been identiﬁed as a potential determinant of vas-
cular diabetes complication risk [24].
Early detection of the disease and timely interventions can
reduce the morbidity and mortality associated with it. Earlier
studies strongly linked DM and diabetic microvascular com-
plication namely nephropathy and retinopathy to Hp poly-
morphism [4,19–20], raising current interests in research to
elucidate the role of Hp phenotypes in DM and its cardiovas-
cular complications. This study was carried out to provide
data on Hp phenotypes and type 2 DM in Egyptians with a72) DM with CAD (N= 48) P-value
) 6 (12.5%) P1 < 0.05; P2 < 0.01; P3 < 0.05
) 12 (25%) P1 NS; P2 < 0.01; P3 < 0.01
) 30 (62.5%) P1 < 0.05; P2 < 0.001; P3 < 0.01
M versus DM with CAD. P values <0.05 and <0.01 are statistically
artery disease.
(N= 120) DM (N= 72) DM with CAD (N= 48)
0.458 0.250
0.542 0.750
Table 5 Relations between risk Factors and haptoglobin phenotypes in patient groups.
Parameters Total patients
(N= 120)
Haptoglobin phenotypes P-value
Hp 1–1
(N= 20)
M± SD
Hp 2–1
(N= 49)
M± SD
Hp 2–2
(N= 51)
M± SD
Age (years) 51.9 ± 7.4 42.6 ± 3.1 47.9 ± 4.3 56.4 ± 5.3 NS
BMI (kg/m2) 31.2 ± 3.9 27.9 ± 1.8 30.43 ± 2.5 33.21 ± 2.1 P1 < 0.05
Disease duration (years) 5.8 ± 2.1 4.9 ± 1.3 6.16 ± 1.8 6.42 ± 1.2 NS
FBS (mg/dL) 156.3 ± 14.5 145.4 ± 11.2 153.7 ± 10.6 159.3 ± 12.1 NS
HbA1c (%) 8.9 ± 2.7 7.2 ± 1.6 9.78 ± 1.7 10.62 ± 1.9 P1 < 0.05; P2 < 0.05
Haptoglobin (mg/dL) 137.8 ± 9.5 129.6 ± 7.6 135.4 ± 12.4 139.1 ± 18.3 NS
CRP (mg/dL) 0.9 ± 0.4 0.68 ± 0.15 0.74 ± 0.03 1.21 ± 0.8 P1 < 0.05; P2 < 0.05
Smoking N (%) 46 (38.3) 7 (35) 19 (38.8) 20(39.2) NS
Hypertension N (%) 57 (47.5) 4 (20) 22(44.9) 31 (60.8) P1 < 0.05; P2 < 0.05; P3 < 0.01
Dyslipidemia N (%) 43 (35.8) 4 (20) 14 (28.8) 25 (49) P1 < 0.05; P2 < 0.05; P3 < 0.01
P1 = Hp2-2 versus Hp1-1; P2 = Hp2-2 versus Hp2-1; P3 = Hp1-1 versus Hp2-1 P values <0.05 and <0.01 are statistically signiﬁcant. NS,
none signiﬁcant; BMI, body mass index; FBS, fasting blood sugar; HbA1c, glycated hemoglobin; CRP, serum C-reactive protein.
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any association with the development of CAD in diabetes.
In this study we demonstrated a relationship between DM
and Hp2-2 phenotype. The frequency of the three major Hp
phenotypes in Egyptian diabetic patients was 16.7% for
Hp1-1, 40.8% for Hp2-1 and 42.5% for Hp2-2.
Several studies on Hp phenotypes, diabetes and its compli-
cations from different parts of the world have been reported,
however, conﬂicting data as regards the association between
Hp phenotypes and predisposition to DM exist. A study on
Jordanian suggested that type II diabetes mellitus is Hp pheno-
type-independent [25], Hp2-1 was the predominant phenotype
among Saudi type 2 diabetics as well as healthy subjects [26],
while a population study by Stern et al., [27] indicated that dia-
betes is associated with the Hp1-1 phenotypes. In agreement to
our results Hp2-2 was the culprit for the development of type 2
diabetes in hypertensive overweight Ghanaians [28]. Ethnic
and racial differences as well as dramatic changes in the life
style which accelerate the onset of type 2 diabetes may override
genetic predisposition and would be the cause of these discrep-
ancies between the study populations. However it may possibly
underscore the need for identiﬁcation of genetic factors that
contribute to differences in susceptibility to and the pathology
of the disease [26,28].
This study demonstrated an increased risk of CAD among
diabetic patients carrying the Hp2-2 genotype compared with
those carrying the other haptoglobin genotypes. The frequency
of Hp2-2 phenotype was greater in patients with CAD than in
those without documented CAD or the controls (P value
<0.01 and 0.001, respectively). We also found that Hp2 allele
frequencies among patients with and without CAD and con-
trols were 0.750, 0.542 and 0.375, respectively.
In fact, individuals with theHp2-2 phenotype appear to have
reduced clearance of the macrophage–Hp–Hb complex, which
affects iron deposition, oxidative stress, and active macrophage
accumulation [29]. These changes would be consistent with an
increased risk of atherosclerotic cardiovascular diseases.
A number of studies have shown increased cardiovascular
disease risk among diabetic individuals carrying theHp2-2 geno-
type. In a case-control analysis of the Strong Heart Study, the
Hp2-2 compared with the Hp1-1 or 2-1 phenotypes was an inde-
pendent predictor of cardiovascular disease among American
Indians with type 2 diabetes, whereas no association wasobserved in the non diabetic population [2]. Also an almost two-
fold risk of the incidence of a major adverse cardiac event within
1 year after percutaneous transluminal coronary angioplasty
among type 2 diabetic patients having Hp2-2 phenotype com-
pared with those of Hp1-1 phenotype had been observed in the
Munich Stent Study [3]. Increased risk ofHp 2-2 phenotypewith
peripheral arterial occlusive disease has been reported as well
[30]. Surprisingly a recent study on Chinese did not ﬁnd any sig-
niﬁcant relationship between Hp phenotypes and CAD [31].
Our results prove that CAD among Egyptian diabetic
patients illustrates the least association with Hp1-1 phenotype
(frequency 12.5%). This ﬁnding is consistent with that of other
investigators who attributed the phenomena to the protective
function of Hp1-1 [2,32]. In agreement with our ﬁnding, Sulei-
man et al., [33] analyzed the Hp phenotypes in diabetic
patients with acute myocardial infarction and demonstrated
that the Hp1-1 phenotype was associated with smaller infarct
size and lower mortality rates at 30 days.
Understanding functional differences between the Hp1 and
Hp2 allelic protein products, particularly in diabetes, may pro-
vide insight into why Hp2-2 diabetic individuals have more
CAD and how this increased burden of disease might be
reduced [34]. First: gross differences in the size of the haptoglo-
bin protein in individuals with the different phenotypes could
account for discrepancy in the oxidative protection afforded
by the different types of haptoglobin. Hp1-1 is markedly smal-
ler than Hp2-2 and may, thus, be better able to sieve into the
extravascular compartment and prevent hemoglobin-mediated
tissue damage at sites of vascular injury [35]. Second: the Hp1
protein is more efﬁcient in preventing oxidation by hemoglobin
and in preventing heme release from the Hp–hemoglobin com-
plex [13,18]. Third: the Hp1 allele is more efﬁcient in promoting
the uptake of the Hp–hemoglobin complex by the CD163 mac-
rophage receptor [13,32,36]. These macrophages have been
described in atherosclerotic lesions and they were suggested
to exhibit an antiatherogenic phenotype when examined
in vivo [37]. Also it has demonstrated that Hp1-1–Hb com-
plexes result in a greater production of the anti-inﬂammatory
cytokine IL-10 as compared with Hp2-2–Hb complexes [38].
In the current study, we have exposed signiﬁcantly higher
serum concentrations of inﬂammatory markers in terms of
CRP and Hp in type 2 diabetic patients with and without asso-
ciated CAD compared to controls. We also notice a signiﬁcant
Haptoglobin phenotypes as a risk factor for CAD 263difference in their levels in the two diabetic groups with the
highest levels in those with associated CAD. Individuals with
speciﬁc Hp phenotypes may respond differently to biological
insults such as inﬂammation and vessel wall degeneration.
The synthesis of Hp may reﬂect a regulatory response to these
pathologic processes [39]. Our data as regards the signiﬁcant
plasma Hp concentrations in diabetics with CAD support this
explanation. In agreement with these results Lee et al., [31]
showed that plasma Hp concentrations were signiﬁcantly
increased in patients with CAD compared with patients who
do not have CAD, and that plasma Hp concentrations were
independently associated with CAD.
Although the levels of Hp did not reach signiﬁcance among
diabetic individuals with different Hp phenotypes yet we found
Hp phenotype 2-2 individuals had trend toward higher levels.
Several studies have shown that the different alleles lead to dif-
ferent levels of circulating Hp protein [19,40]. However Moh-
ieldein et al., [26] showed that serum Hp concentrations
among their diabetic and control subjects were free of pheno-
typic-dependence.
Different methods may overestimate or underestimate Hp
concentration in different phenotype groups .Unfortunately
we measured the total serum Hp level rather than phenotype
speciﬁc protein which may explain differences of Hp concen-
tration between different phenotypes and that mentioned in
other published studies [19,40].
The pathogenesis of human hypertension is considered
complex and multifactorial and results from the combined
effect of predisposing genetic and environmental risk factors
[41]. Recently Boretti et al. [42] reported that cell-free plasma
Hb has potent oxidative properties that are associated with
hypertensive effects. They also found that increasing the levels
of haptoglobin in the circulation reduced this oxidative stress
and limited both the hypertensive effects and the renal insufﬁ-
ciency associated with plasma hemoglobinemia.
It had been documented that hypertensive patients carrying
Hp2-2 are more likely to accumulate atherosclerotic lesions of
the coronary or peripheral arteries, despite comparable lipid
levels, smoking habits and BMI [43]. Hp binds to ApoA1 in
the same location as lecithin-cholesterol acyltransferase
(LCAT), subsequently decreasing LCAT activity and therefore
limiting high density lipoprotein (HDL) maturation. This
inhibits reverse cholesterol transport causing HDL to become
proatherogenic [44]. In addition, the tethering of Hb to HDL
via Hp–ApoA1 allows the oxidation of HDL and its acquisi-
tion of proatherogenic and proinﬂammatory properties [45] .
The current data suggest an association between function-
ally distinct phenotypes of haptoglobin gene and various
CAD risk factors. Hypertension and dyslipidemia were more
prevalent in diabetic individuals with Hp2-2 phenotype as well
as higher levels of BMI and HbA1c were observed. There have
been conﬂicting reports regarding the role of Hp polymor-
phism in hypertension. In agreement with our ﬁnding an asso-
ciation between Hp2-2 phenotype and higher occurrence of
refractory hypertension was found [46]. A Brazilian study
showed that individuals of the Hp1-1 phenotype had an
approximately 3-fold increase in essential hypertension [47]
however a more recent one revealed an approximately four
fold increase in refractory hypertension in type 2 diabetics with
Hp type 2-1 [48]. These conﬂicting reports may be due to the
cross sectional nature of the studies and indicate that addi-
tional prospective studies need to be carried out.5. Conclusion and recommendation
The present study conducted in Egyptian populations with
type 2 DM shows that: (i) there is increased frequency of
Hp2-2 phenotype among type 2 DM patients. (ii) Serum levels
of inﬂammatory markers in terms of CRP and Hp are signiﬁ-
cantly higher in type 2 diabetic patients, those with CAD dem-
onstrated the highest levels. (iii) Higher levels of BMI, HbA1c
as well as hypertension and dyslipidemia are more prevalent in
diabetic individuals with Hp2-2 phenotype. (iv) Hp phenotype
2-2 is deemed to be a susceptibility gene for the development of
CAD in type 2 DM. Whether to be part of the CAD risk strat-
iﬁcation algorithm or avenue of new preventive and therapeu-
tic options for type 2DM need further wide scale multicenter
studies free of bias.Conﬂict of interest
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